Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab in moderate to very severe COPD (RESOLUTE)
NCT04053634Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2019
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 30
01
Overview
A Phase 3 trial of benralizumab in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Started Aug 2019; status: completed.
02
Drugs
benralizumab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04053634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04053634.